Abstract:BACKGROUND: Sevoflurane is the most widely used inhalational anesthetic in pediatric medicine. Despite this, sevoflurane has been reported to exert potentially neurotoxic effects on the developing brain. Clinical interventions and treatments for these effects are limited. Tanshinone IIA (Tan IIA), extracted from Salvia miltiorrhiza (Danshen), has been documented to alleviate cognitive decline in traditional applications. Therefore, we hypothesized that preadministration of Tan IIA may attenuate sevoflurane-induced neurotoxicity, suggesting that Tan IIA is a new and promising drug capable of counteracting the effects of cognitive dysfunction produced by general anesthetics. METHODS: To test this hypothesis, neonatal C57 mice (P6) were exposed to 3% sevoflurane for 2 hours with or without Tan IIA pretreatment at a dose of 10 mg/kg or 20 mg/kg for 3 consecutive days. Cognitive behavior tests such as open field tests and fear conditioning were performed to evaluate locomotor and cognitive function at P31 and P32. At P8, other separate tests, including TdT mediated dUTP Nick End Labeling (TUNEL) assay, immunohistochemistry, Western blotting, enzyme-linked immunosorbent assay, and electron microscopy, were performed. The mean differences among groups were compared using 1-way analysis of variance followed by Bonferroni post hoc multiple comparison tests. RESULTS: Repeated exposure to sevoflurane leads to significant cognitive impairment in mice, which may be explained by increased apoptosis, overexpression of neuroinflammatory markers, and changes in synaptic ultrastructure. Interestingly, preadministration of Tan IIA ameliorated these neurocognitive deficits, as shown by increased freezing percentages on the fear conditioning test (sevoflurane+Tan IIA [20 mg/kg] versus sevoflurane, mean difference, 19, 99% confidence interval for difference, 6.4–31, P < .0001, n = 6). The treatment also reduced the percentage of TUNEL-positive nuclei (sevoflurane versus sevoflurane+Tan IIA [20 mg/kg], 2.6, 0.73–4.5, P = .0004, n = 6) and the normalized expression of cleaved caspase-3 (sevoflurane versus sevoflurane+Tan IIA [20 mg/kg], 0.27, 0.02–0.51, P = .0046, n = 5). Moreover, it attenuated the production of the neuroinflammatory mediators interleukin (IL)-1&bgr; and IL-6 (normalized sevoflurane versus sevoflurane+Tan IIA [20 mg/kg]: IL-1&bgr;: 0.75, 0.47–1.0; P < .0001; IL-6: 0.66, 0.35–0.97; P < .0001; n = 10 per group). Finally, based on measurements of postsynaptic density, the treatment preserved synaptic ultrastructure (sevoflurane+Tan IIA [20 mg/kg] versus sevoflurane, 42, 20–66; P < .0001; n = 12 per group). CONCLUSIONS: These results indicate that Tan IIA can alleviate sevoflurane-induced neurobehavioral abnormalities and may decrease neuroapoptosis and neuroinflammation.

Triiodothyronine attenuates neurocognitive dysfunction induced by sevoflurane in the developing brain of neonatal rats

Role of Autophagy in Sevoflurane-Induced Neurotoxicity in Neonatal Rat Hippocampal Cells.

Tanshinone IIA Attenuates Sevoflurane Neurotoxicity in Neonatal Mice.

Neonatal Exposure to Low-Dose (1.2%) Sevoflurane Increases Rats’ Hippocampal Neurogenesis and Synaptic Plasticity in Later Life

TRPV1 Antagonist Prevents Neonatal Sevoflurane-Induced Synaptic Abnormality and Cognitive Impairment in Mice Through Regulating the Src/Cofilin Signaling Pathway

Neonatal Exposure to Sevoflurane Expands the Window of Vulnerability to Adverse Effects of Subsequent Exposure to Sevoflurane and Alters Hippocampal Morphology Via Decitabine-Sensitive Mechanisms.

Resveratrol ameliorates sevoflurane-induced cognitive impairment by activating the SIRT1/NF-κB pathway in neonatal mice

Perinatal Supplementation With Omega-3 Polyunsaturated Fatty Acids Improves Sevoflurane-Induced Neurodegeneration And Memory Impairment In Neonatal Rats

Effects of different duration of sevoflurane anesthesia in neonatal period on long-term cognitive func-tion and hippocampal synaptic plasticity in rats

Low-dose sevoflurane promotes hippocampal neurogenesis and facilitates the development of dentate gyrus-dependent learning in neonatal rats.

Pretreatment with Tetramethylpyrazine Alleviated the Impairment of Learning and Memory Induced by Sevoflurane Exposure in Neonatal Rats

7,8-Dihydroxyflavone ameliorates cognitive impairment induced by repeated neonatal sevoflurane exposures in mice through increasing tau O-GlcNAcylation

Sevoflurane Induces Short‐term Changes in Proteins in the Cerebral Cortices of Developing Rats

Subclinical Concentrations of Sevoflurane Reduce Oxidative Stress but Do Not Prevent Hippocampal Apoptosis

Repeated neonatal exposure to sevoflurane induces age-dependent impairments in cognition and synaptic plasticity in mice

Neuronal Apoptosis May Not Contribute to the Long-Term Cognitive Dysfunction Induced by a Brief Exposure to 2% Sevoflurane in Developing Rats.

Single Sevoflurane Exposure Decreases Neuronal Nitric Oxide Synthase Levels in the Hippocampus of Developing Rats.

Effect of hippocampal DNA methyltransferases in sevoflurane induced neonatal cognitive impairments

Tau Contributes to Sevoflurane-induced Neurocognitive Impairment in Neonatal Mice.

Role of Cdk5-CRMP pathway in sevoflurane-induced dendritic develop-mental disorder of neurons in prefrontal cortex of neonatal rats

Subsequent Maternal Separation Exacerbates Neurobehavioral Abnormalities in Rats Neonatally Exposed to Sevoflurane Anesthesia.